REMS Management

Return to Policy & Issues

The FDA requires manufacturers to implement Risk Evaluation and Mitigation Strategy (REMS) programs for certain high-risk drugs to ensure that products’ benefits outweigh their risks. REMS can vary widely in levels of complexity, ranging from a simple medication guide to much more robust programs that include a communication plan, patient registry, and patient monitoring.

PBMs and specialty pharmacies help drug manufacturers design, implement, and evaluate REMS programs. Without proper management, REMS programs could become overly restrictive and prevent patients from accessing important drug therapies. If REMS requirements are too complicated and cumbersome for patients and their prescribers to follow, it is possible that less effective drugs may be used instead. The ultimate goal of a successful REMS program is to get the right therapy to the right patients at the right time.

Research

Press Releases

Related Card Stacks

What services do specialty pharmacies provide?

Specialty pharmacy services are designed for a small, but growing population of patients with relatively complex and chronic diseases that require expensive and challenging drug regimens.

Learn More

What tools do PBMs use?

The total costs and utilization of specialty drugs will have a substantial impact on overall health care costs during the next decade.

Learn More

FDA’s Impact on Drug Competition – Matrix Global Advisors

While the FDA's core mission is to protect the public heath by ensuring the safety and efficacy of drugs (among other products), the agency also makes it a priority to facilitate drug innovation.

Learn More